RMC-4998 treatment also increased the presence of CD86+MHCII+ and PD-L1+ interstitial MΦs with the RMC-4550 treated tumours having a distinct increased proportion of these subsets (Fig. 5b). This evidence concerns the gene CD86 and neoplasm.